A Phase I Study of Oral Ixabepilone in Subjects With Advanced Cancer

Inclusion Criteria:

* Confirmed diagnosis of solid tumor malignancy unresponsive to current treatment options
* Measurable or nonmeasurable disease as defined by Response Evaluation Criteria in Solid Tumors
* Lapse of at least 1 week since minor surgery and of at least 3 weeks since major surgery and radiation therapy
* Eastern Cooperative Oncology Group performance status of 0-1
* Lapse of at least 4 weeks since immunotherapy or chemotherapy
* Negative pregnancy test result within 72 hours of study drug administration for any woman of childbearing potential (WOCBP)

Exclusion Criteria:

* WOCBP unable or unwilling to use birth control during study and for up to 4 weeks after study completion
* Women who are pregnant or breastfeeding
* Fertile men not using effective birth control with partners who are WOCBP
* Gastrointestinal(GI) disease or GI tract surgery that could impact drug absorption
* Inability to swallow capsules
* Inability to be venipunctured or to tolerate venous access
* Known symptomatic brain metastases
* Common Terminology Criteria for Adverse Events Grade 2 or greater neuropathy or history of Grade 3 or greater neuropathy
* Psychiatric conditions inhibiting compliance with protocol requirements
* Uncontrolled medical disorder or active infection that would impair participant's ability to receive protocol therapy or whose control may be jeopardized by the study treatment protocol
* Inadequate hematologic, hepatic, or renal function
* History of significant drug allergy
* Previous exposure to ixabepilone
* Exposure to any investigational drug or placebo within 4 weeks of enrollment
* Concurrent chemotherapy regimen
* Use of cytochrome P4503A4 inhibitors or inducers within 2 weeks of treatment initiation (unless approved by medical monitor)
* Use of steroids (except as antiemetic)
* Prisoners or subjects involuntarily detained for treatment